Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis

@inproceedings{Chen2012DovitinibPT,
  title={Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis},
  author={Zhiyuan Chen and Ming Shi and Li-Xia Peng and Wei Wei and Xin-jian Li and Zhi-xing Guo and Shu-hong Li and Chong Zhong and C N Qian and Rong-ping Guo},
  booktitle={Journal of Translational Medicine},
  year={2012}
}
Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is currently in clinical trials for the treatment of hepatocellular carcinoma (HCC). In this study, we used five HCC cell lines and five endothelial cell lines to validate molecular and cellular targets of dovitinib. Tumor growth and pulmonary metastasis were significantly suppressed in an… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations